Peripheral nerve injuries, whether sustained through avulsive neurotmesis, sharp or projectile penetrating mechanisms, or iatrogenic injury, can be devastating. Ignoring for a moment the miraculous physiologic complexities of our muscular and skeletal symptoms, individual muscles and bones are, quite frankly, “dumb,” providing a specific and limited set of mechanical functions. Peripheral nerves, on the other hand, are dizzyingly complex—carrying critical afferent and efferent information along a living system of electrical circuits that we take for granted during any activity we do, and even during our periods of inactivity. Despite the perceived predilection to injury, our nerves are quite robust—the majority of nerve tissue being biological insulation in the form of myelin sheaths and vascularized connective tissue that supports and nourishes our nerves, allowing them to glide within our limbs so that we don’t cause a nerve palsy during strenuous or contorted activities.

Historically, the prognosis for complete nerve injuries (either internal or external transections) has not been spectacular. Yes, direct repairs can sometimes restore nerve function rather dramatically, particularly for distal injuries in younger patients. However, proximal injuries, in mixed motor and sensory nerves, and/or involving “critical-sized” defects of 4 cm to 7 cm or longer, continue to be challenging, and the prognosis remains poor for most patients who experience these injuries.

Numerous advances in the last two decades have finally started to “move the needle” and improve the prognosis for the surgical management of peripheral nerve injuries. Viable off-the-shelf surgical conduits for short-segment gaps (or for overwrapping repair sites to limit scarring and axonal escape) have become widely available, and offer results comparable to direct repair for short-segment deficits, particularly for sensory nerves [4, 6]. Perhaps better still, decellularized human allograft nerve grafts (Avance, AxoGen, Inc, Alachua, FL, USA) have demonstrated meaningful sensory and motor recovery (M4-M5, representing near-normal to normal strength against resistance), potentially equivalent to autograft (or even direct repair [10]) without donor site limitations or morbidity, for defects as long as 5 cm [1, 6, 7]. Investigators have focused with renewed enthusiasm on the immunosuppressant FK506 (tacrolimus) based on better-than expected neurologic recovery in patients undergoing whole-hand transplants [2]. Tacrolimus appears to enhance nerve regeneration through a noncalcineurin dependent pathway, and has been studied intermittently for decades for this purpose [12, 13]. Perhaps most exciting, we may finally be approaching the event horizon of the era of sutureless (or minimal-suture) nerve repair.

Why the need for minimal suture nerve repair? Microsuturing of nerves is fraught with difficulty, and can result in undesired complications such as scarring, fascicle ligation by the suture, or gapping and axonal escape resulting in a neuroma in continuity, particularly when not augmented with a nerve conduit, vein graft, or similar envelope. An alternative approach like fibrin glue has demonstrated equivalent or superior results to suture repair in numerous animal studies and one human study [11], but concerns about lack of tensile strength and secondary nerve gapping persist [11]. Beyond fibrin glue, we have seen poly(ethylene glycol [PEG]) hydrogel improve resistance to gapping, show equivalence to suture, and demonstrate better results than fibrin sealant [8]. The use of photochemical tissue bonding (PTB) represents an even-more-promising technique using a nonthermal, Nd/YAG laser, nonimmunogenic amnion-derived wrap, and a photoactive dye. Animal studies [5, 9] suggest improved electrophysiological outcomes, histologic recovery, and even gait compared to direct suture repair. A more-recent study [3] created a 15 mm defect in rat sciatic nerves and repaired the defect with reversed isografts. PTB repairs outperformed suture repair for both immediate and delayed (30 days) reconstruction with regard to muscle mass retention and histomorphometric recovery [3]. Animal studies of escalating complexity continue to be performed for this technique, with the hope of human trials commencing shortly.

Other interventions to improve nerve repair and reconstruction outcomes are being investigated, as well, and those mentioned above are by no means an exhaustive list. It also seems likely that no single modality will lead us to the holy grail of normal (or nearly normal) function following proximal or long-segment peripheral nerve injury. Perhaps most importantly, many of these newer techniques can be used concurrently and may ultimately prove complimentary. For example, one can imagine using PTB with allografts, reinforced with fibrin or PEG hydrogel glue, in a patient treated with low-dose tacrolimus postoperatively to improve overall recovery.

Ultimately, we need to ask ourselves “if this injury happened to me, could I still be an orthopaedic surgeon?” Until the answer is yes, we need to keep pushing the clinical and translational research envelope. But someday soon, stitching up a nerve repair or reconstruction may not require a stitch at all.